Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Items 401–500 of 670
Lee, C. M., Choe, P. G., Kang, C. K., Lee, E., Song, K., Bang, J. H., Kim, E. S., Kim, H. B., Kim, N. J., Kim, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1106664 · Cited by 4
Cotter, C. A., Americo, J. L., Earl, P. L., & Moss, B. (2023) · npj Vaccines · doi:10.1038/s41541-023-00645-7 · Cited by 4
Tawinprai, K., Jungsomsri, P., Pinijnai, O., Tavonvunchai, F., Lievjaroen, A., Suwannaroj, P., Siripongboonsitti, T., Porntharukchareon, T., Sornsamdang, G., & Ungtrakul, T. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2206360 · Cited by 4
“The AZD1222 vaccine from SK Bioscience Co Ltd, Republic of Korea, contained 5 × 10(10) viral particles.(4) All vaccines were administered intramuscularly into the deltoid muscle using the standard dose.”
MethodHoang, T. N. A., Quach, H., Hoang, N. V., Tran, V. T., Thái, P. Q., & VOGT, F. M. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.22.2200706 · Cited by 4
Monin, M. B., Gorny, J. G., Berger, M., Baier, L. I., Zhou, T., Mahn, R., Sadeghlar, F., Möhring, C., Boesecke, C., van Bremen, K., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1065 · Cited by 3
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S
Jacob-Dolan, C., Lifton, M. A., Powers, O. C., Miller, J. J., Hachmann, N. P., Vu, M. L., Surve, N., Mazurek, C. R., Fisher, J. L., Rodrigues, S. L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109716 · Cited by 7
Lee, K. Y., Song, K., Lee, K. H., Baek, J. Y., Kim, E. S., Song, Y. G., Kim, Y. C., Park, Y. S., Ahn, J. Y., Choi, J. Y., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.003 · Cited by 4
Cruz, V. A., Guimarães, C. F., Rêgo, J., Machado, K. L. L. L., Miyamoto, S. T., Burian, A. P. N., Dias, L. H., Pretti, F., Batista, D. C. F. A., Mill, J. G., et al. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00397-5 · Cited by 7
Drug-induced liver injury after covid-19 mRNA vaccine: case report
Rivera-Tenorio, A., Díaz, H. O. H., Triana, P. A., Posso, J. G., Osorio-Gómez, A. M., Velandia, J. E. S., Acosta, W. S., & Portillo‐Miño, J. D. (2022) · Colombia medica · doi:10.25100/cm.v53i3.5187 · Cited by 4
Arregocés-Castillo, L., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón, L. E., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3978556 · Cited by 4
Withdrawn: A systematic review of autopsy findings in deaths after COVID-19 vaccination
Hulscher, N., Alexander, P. E., Amerling, R., Gessling, H., Hodkinson, R., Makis, W., Risch, H. A., Trozzi, M., & McCullough, P. A. (2024) · Forensic Science International · doi:10.1016/j.forsciint.2024.112115 · Cited by 10
RetractedAddetia, A., Schäfer, A., Sprouse, K. R., Valdez, A., Taylor, A., Navarro, M.-J., Brown, J. T., Leaf, E. M., Miranda, M. C., Walls, A. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.652904 · Cited by 4
Meyer, J., Hoerauf, A. M., Dubiel, A. E., Kovačević, P., Trudić, A., Primorac, D., Hübner, M. P., Adjobimey, T., & Parčina, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727049 · Cited by 4
Aboshi, M., Kawakami, D., Kono, K., Nishiyama, A., Nogimori, T., Sunada, Y., Matsuda, K., Sekida, T., Suga, S., Smith, J., et al. (2026) · iScience · doi:10.1016/j.isci.2026.114766 · Cited by 3
Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design
Grewe, I., Zoran, T., & Addo, M. M. (2026) · Immunological Reviews · doi:10.1111/imr.70098 · Cited by 6
“Results from a large phase 3 clinical study showed that the efficacy of the ChAdOx1 nCoV-19 vaccine was similar in male and female vaccinees [66].”
Campos, G. R. F., Almeida, N. B. F., Filgueiras, P. S., Corsini, C. A., Gomes, S. V. C., de Miranda, D. A. P., de Assis, J. V., Silva, T. B. D. S., Alves, P. A., Fernandes, G. D. R., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1371695 · Cited by 3
Wu, P., Lin, W.-C., Wang, C., Chung, W.-H., & Chen, C. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110220 · Cited by 3
Neto, F. L., Mercadé‐Besora, N., Raventós, B., Pérez‐Crespo, L., de Castro, G., Ranzani, O., & Duarte‐Salles, T. (2024) · Nature Communications · doi:10.1038/s41467-024-49285-y · Cited by 6
Wang, G., Zhao, K., Zhao, X., Cui, Y., He, P., Zhang, T., Wang, Y., Shi, R., Li, Y., Wang, Q., et al. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2456231 · Cited by 3
“Moreover, SCTV01C may offer a superior safety and reacto-genicity profile when compared to authorized mRNA vaccines and adenovirus vector vaccines [21–25].”
Mkhize, N. N., Zhang, B., Brackett, C., Elyanu, P., Tapley, A., Dadabhai, S. S., Hu, J., Do, B. T. N., Schuster, D. J., Heptinstall, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63948-4 · Cited by 6
“…CoPs against COVID-19 in four randomized, placebo-controlled vaccine ef fi cacy trials 16 – 21 , consistently showing that both markers are CoRs of COVID-19 and CoPs of vaccine protection against COVID-19 22 – 29 , which has also been supported by other individual-level 30 – 32 and…”
Self-citationChan, C. C., Lin, C., Chang, C., & Chu, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1014250 · Cited by 3
“In addition, no anaphylaxis events were reported (5).”
BackgroundAn Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination
Chowdhury, P., Bhattacharya, S., Gogoi, B., Veeranna, R. P., & Kumar, S. (2022) · Vaccines · doi:10.3390/vaccines10101639 · Cited by 3
Scotto, R., Lanzardo, A., Buonomo, A., Pinchera, B., Cattaneo, L., Sardanelli, A., Mercinelli, S., Viceconte, G., Perrella, A., Esposito, V., et al. (2022) · Vaccines · doi:10.3390/vaccines10122043 · Cited by 2
Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
Mikołajczyk, M., Lewandowski, R. A., & Goncharuk, A. G. (2022) · Vaccines · doi:10.3390/vaccines11010093 · Cited by 2
Müllerová, H., Medin, J., Arnold, M., da Silva, H. G., Kumar, S. R., Nord, M., Hubbard, R., & de Lusignan, S. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063645 · Cited by 3
Cheung, C. K. M., Law, K. W. T., Law, A. W. H., Law, M. F., Ho, R., & Wong, S. H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00339 · Cited by 3
Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens
Alkharaan, H., Alqarni, H., Aldosari, M., Alsaloum, M., Aldakheel, G., Alenazi, M. W., & Alharbi, N. K. (2023) · Vaccines · doi:10.3390/vaccines11040744 · Cited by 3
Doneddu, P. E., Briani, C., Cocito, D., Manganelli, F., Fabrizi, G. M., Matà, S., Mazzeo, A. T., Fazio, R., Benedetti, L., Luigetti, M., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15811 · Cited by 5
“Of the 336 patients included, 307 (91%; 260 with CIDP, 47 with MMN) underwent SARS- CoV2 vaccination, including 269 (88%) patients with BNT162b2 (Pfizer/BioNTech) [15], 28 (9%) patients with mRNA1273 (Moderna) [16] and 10 (3%) patients with ChAdOx1 (AstraZeneca) [14].”
BackgroundLyons, J., Nafilyan, V., Akbari, A., Bedston, S., Harrison, E. M., Hayward, A. C., Hippisley‐Cox, J., Kee, F., Khunti, K., Rahman, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285979 · Cited by 4
“The vaccines efficacy were tested generally on younger healthier volunteers in clinical trials [10].”
BackgroundMason, P., Rizzuto, R., Iannelli, L., Baccaglini, F., Rizzolo, V., Baraldo, A., Melloni, B., Maffione, F., Pezzoli, C., Chiozza, M. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11050951 · Cited by 3
A Critical Assessment of COVID-19 Genomic Vaccines
Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4
Efficacy of COVID-19 Vaccines against the Omicron Variant of SARS-CoV-2: A Review
Rajsri, K. S., Singh, M., & Rao, M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00023 · Cited by 3
Ruenkham, A., Uitrakul, S., Oberdorfer, P., Okonogi, S., & Katip, W. (2023) · Vaccines · doi:10.3390/vaccines11091458 · Cited by 3
Altered liver function test after Covid ‐19 vaccines: A retrospective control group study
Jabif, F. E., Vallone, M. G., Stanek, V. C., Lopez, M. P., Sobenko, N., Villamil, A., & Ratti, M. F. G. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5696 · Cited by 4
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?
Harel, R., & Itchaki, G. (2023) · Acta Haematologica · doi:10.1159/000534540 · Cited by 4
Kulkarni, P. S., Padmapriyadarshini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B., Gogtay, N., Tambe, M., Lalwani, S. K., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2304974 · Cited by 4
“18 To conclude, SII-ChAdOx1 nCoV-19 is highly immunogenic and has an acceptable long-term safety profile, but booster doses are likely to be needed due to immunological waning 6 months after primary series vaccination.”
Self-citationRusmil, K., Fadlyana, E., Girsang, R. T., Adrizain, R., Rahmadi, A. R., Suryadinata, H., Putra, M. G. D., Fulendry, F. P., Nashsyah, D. T., Utami, R. K., et al. (2024) · Vaccines · doi:10.3390/vaccines12050540 · Cited by 3
Shoemaker, K., Soboleva, K., Branche, A. R., Shankaran, S., Theodore, D., Bari, M., Ezeh, V., Green, J. A., Kelly, E. J., Lan, D., et al. (2024) · Vaccines · doi:10.3390/vaccines12080883 · Cited by 5
“Immunogenicity data up to study day 180 have been previously reported [11,16].”
BackgroundMethodInfluentialSelf-citationSARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico
Barrientos-Flores, C. D. J., Vilar‐Compte, D., Martínez-Rivera, N. C., Villaseñor-Echavarri, R., & Martin‐Onraët, A. (2024) · Vaccines · doi:10.3390/vaccines12101163 · Cited by 3
“At the end of 2020, the first vaccines targeting SARS-CoV-2 were approved, and trials reported high safety, tolerability, and efficacy, with a reduction in mortality [3–5].”
BackgroundParish, L. A., Rele, S. S., Hofmeyer, K. A., Luck, B. B., & Wolfe, D. (2025) · Vaccines · doi:10.3390/vaccines13010073 · Cited by 6
“Likewise, the COVID-19 vaccine based on the ChAdOx-1 vector was initially estimated at 74% effective at preventing symptomatic disease 15 days or later after the second dose [29].”
Yang, C., Li, E., Guo, X., Xie, W., Wang, Y., Huang, X., Chiu, S., & Wu, X. (2025) · ACS Nano · doi:10.1021/acsnano.4c17269 · Cited by 3
Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network
Atmar, R. L., Abate, G., Deming, M. E., George, S. L., Fleming, A. B., Frey, S. E., Lyke, K. E., Stephens, D. S., del Río, C., & Sahly, H. M. E. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf380 · Cited by 3
COVID-19 and the Unraveling of Experimental Medicine - Part II
Thorp, K. E., & Thorp, J. A. (2022) · The Gazette of Medical Sciences · doi:10.46766/thegms.pubheal.22022804 · Cited by 6
Jeong, S., Hong, S., Oh, T.-H., Woo, S. H., Lee, W. J., Kim, D., & Jeong, W. J. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.04.022 · Cited by 4
“In a clinical trial regarding the Pfizer/BioNTech COVID-19 vaccine, fever was reported after the second dose by 16% of the younger vaccine recipients and by 11% of the older recipients [2], and in a study of the AstraZeneca vaccine, fever was reported by 7% of all vaccine recipients [9].”
Navarro, A. P., Pilkington, V., Pepperrell, T., Mirchandani, M., Levi, J., & Hill, A. M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac408 · Cited by 3
“(VVnr) Variable 44 087 (5) [25, 26] UK, Brazil, South Africa, USA, Chile, Peru 2.”
Bou-ouhrich, Y., & Charra, B. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.43.124.32265 · Cited by 3
Hantrakun, N., Sinsakolwat, P., Tantiworawit, A., Rattarittamrong, E., Rattanathammethee, T., Hantrakool, S., Piriyakhuntorn, P., Punnachet, T., Niprapan, P., Wongtagan, O., et al. (2023) · Vaccines · doi:10.3390/vaccines11030692 · Cited by 3
“The ChAdOx1 nCoV-19 adenoviral vector-based vaccine (Oxford/AstraZeneca) demonstrated efficacy in preventing symptomatic and severe COVID-19 in older adults [5].”
Campbell, E., Dobkin, J., Osorio, L., Kolloli, A., Ramasamy, S., Kumar, R., Sant’Angelo, D. B., Subbian, S., Denzin, L. K., & Anderson, S. (2023) · Vaccines · doi:10.3390/vaccines11040832 · Cited by 3
“S and AZD1222 elicit lower initial antibody responses [15], but protection seems to be more durable as immunological readouts remain relatively constant over time [12,16].”
BackgroundEffects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes
Shapiro, J. R., Roberts, C. W., Arcovio, K., Reade, L., Klein, S. L., & Dhakal, S. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_4 · Cited by 8
Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of ConcernPreprint
Koen, A., Izu, A., Baillie, V., Kwatra, G., Cutland, C. L., Fairlie, L., Padayachee, S., Dheda, K., Barnabas, S., Bhorat, Q., et al. (2022) · medRxiv · doi:10.1101/2022.07.18.22277743 · Cited by 2
“We demonstrate high VE against WT SARS-CoV-2 infection, in line with previous findings [3, 5].”
BackgroundResultSelf-citationBlack, B. S., & Thaw, D. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155493 · Cited by 3
ChAdOx1 nCoV‐19 vaccination generates spike‐specific CD8+ T cells in aged mice
Foster, W. S., Newman, J., Thakur, N., Spencer, A. J., Davies, S., Woods, D., Godfrey, L., Ross, S. H., Sharpe, H. J., Richard, A. C., et al. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12645 · Cited by 4
“Despite this, the phase 3 trial of ChAdOx1 nCoV-19 found that vaccine efficacy was maintained in participants over 65 years of age, despite lower humoral immunity.(15) During aging, the CD8 T-cell compartment changes; thymic involution occurs in early adulthood and reduces the supply of new na€ıve T cells, and later,…”
Chen, Y., Shen, Y.-S., Fang, C., Chan, T.-T., Wu, S., Wang, J., Wu, S., & Liu, C. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100559 · Cited by 3
“HEK293 cell lines have also been used to produce several FDA/EMA-approved biologics, including SARS-CoV-2 vaccines [36,37].”
MethodBolu, O. O., Alo, O. D., Iwara, E., Longley, A. T., Hadley, I., Ogar, C. K., Ezekwe, C., Elemuwa, U., Adedokun, O. A., Ramadhani, H. O., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126907 · Cited by 2
Making Universal Vaccines and Antibodies Through Glycoengineering
Krasnova, L. B., & Wong, C. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4542-0_3 · Cited by 2
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2
Bando, T., Ikematsu, H., Kawai, N., Shibao, K., Mizuguchi, M., Amemiya, T., Tsuchiya, S., Oribe, Y., Lee, W. J., Maeda, T., et al. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102798 · Cited by 2
Corey, L. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502975122 · Cited by 2
“OWS delivered over 1 billion doses of multiple different vaccines as well as sev - eral effective monoclonal antibodies ( 4 – 9 ) that saved mil - lions of lives worldwide ( 10 , 11 ).”
Self-citationChappell, K. J., Mordant, F. L., Amarilla, A. A., Modhiran, N., Liang, B., Li, Z., Lackenby, J. A., Jaberolansar, N., O’Donnell, J. S., Kienzle, V., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf568 · Cited by 2
“During the COVID-19 pandemic, mRNA vaccines, viral-vectored vaccines, and subunit vaccines were all shown to provide protection against severe disease [18–21]; however, this may not be the case during a future pandemic.”
Imrie, R. M., Bissett, L. A., Raveendran, S., Manali, M., Amat, J. A. R., Mojsiejczuk, L. N., Logan, N. A., PARK, A. W., Baguelin, M., Viana, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69988-8 · Cited by 2
Loh, E., Michael, S. A., Beetson, R., & Schmidt, A. (2021) · BMJ Leader · doi:10.1136/leader-2021-000572 · Cited by 2
Limpawittayakul, P., Sungkasubun, P., Chaiwiriyawong, W., Supavavej, A., Weerasubpong, B., Siripaibun, J., Phanthunane, C., Lamlertthon, W., Ungtrakul, T., Tawinprai, K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2104058 · Cited by 2
Çomo, N., Mechili, E. A., Qato, M., Meta, E., Strakosha, A., Fico, A., Kenga, A., Patelarou, A. E., & Patelarou, E. (2022) · Vaccines · doi:10.3390/vaccines10111851 · Cited by 3
COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance
Massy, N., Atzenhoffer, M., Boulay, C., Pecquet, P.-E., Ledys, F., Cracowski, J., Masmoudi, K., Lepelley, M., & Gras‐Champel, V. (2023) · Therapies · doi:10.1016/j.therap.2023.01.005 · Cited by 3
Velhal, G. D., Kamath, Y. V., Agrawal, A. S., Vora, D. S., & Dwivedi, V. R. (2022) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_93_22 · Cited by 2
“Other adverse events followed a similar pattern, a trend reflected in Kim et al. (2021)[6] and Falsey et al. (2021).”
ResultNo association of malignant B‐cell non‐Hodgkin lymphomas with ipsilateral SARS‐CoV ‐2 vaccination
Claaß, L. V., Mayr, P., Paschold, L., Weber, T. E., Terziev, D., Jehs, B., Brill, R., Dober, J., Märkl, B., Wickenhauser, C., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5687 · Cited by 1
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
Rodilla, A. M., Tavolacci, S. C., Cagan, J., Shah, T., Mittan, S., Mack, P. C., & Hirsch, F. R. (2023) · Vaccines · doi:10.3390/vaccines11050969 · Cited by 2
Translatability scoring in prospective and retrospective COVID drug development cases
Wendler, A., & Wehling, M. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03517-0 · Cited by 2
“11 Fair to good chance of success Success: Phase III successful [86], 100% protection against mortality and severe disease, approved by FDA and EMA”
BackgroundGim, H., Lee, S., Seo, H., Park, Y., & Chun, B. C. (2023) · Vaccines · doi:10.3390/vaccines11091408 · Cited by 3
Makonokaya, L., Kapanda, L., Woelk, G. B., Chauma-Mwale, A., Kalitera, L. U., Nkhoma, H., Zimba, S. B., Chamanga, R. K., Golowa, C., Machekano, R. N., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20237123 · Cited by 2
“AZD1222, another adenovirus-vectored vaccine, is administered in two doses with an efficacy of 74.0% [15].”
BackgroundMethodInfluentialAlleva, D., Feitsma, E., Janssen, Y., Boersma, H., Lancaster, T. M., Sathiyaseelan, T., Murikipudi, S., Delpero, A., Scully, M. M., Ragupathy, R., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00830-2 · Cited by 2
Choi, S. J., Lee, W., Kim, S. C., Jo, H.-Y., Park, H., Kim, H. B., Park, W., Park, S. H., Ko, J., & Lee, J. S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.019 · Cited by 2
Maxwell, J. W. C., Stockdale, S., Stewart, E. L., Ashley, C. L., Smith, L. J., Steain, M. C., Triccas, J. A., Byrne, S. N., Britton, W. J., Ashhurst, A. S., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00544 · Cited by 2
Luxi, N., Ciccimarra, F., Bellitto, C., Raethke, M., van Hunsel, F. P. A. M., Lieber, T., Mulder, E., L’Abbate, L., Marques, F. B., Furci, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12091059 · Cited by 2
Rappaport, A., Bekerman, E., Boucher, G. R., Sung, J., Carr, B., Corzo, C. A., Larson, H., Kachura, M. A., Scallan, C. D., Geleziunas, R., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae052 · Cited by 3
Stabilizing Prefusion SARS-CoV-2 Spike by Destabilizing the Postfusion Conformation
Chakraborty, D., Singh, R., Rajmani, R. S., Kumar, S., Ringe, R. P., & Varadarajan, R. (2025) · Vaccines · doi:10.3390/vaccines13030315 · Cited by 5
“With the exception of the chimpanzee adenovirus viral vectored vaccine [21–23] which used the wildtype Spike, all other clinically approved Spike-based platforms have employed a stabilized version of Spike containing at least two proline mutations (Spike-2P) as the sole immunogen, as described…”
Blass, E., Colarusso, A., Aïd, M., Larocca, R. A., Reeves, R. K., & Barouch, D. H. (2025) · Journal of Virology · doi:10.1128/jvi.00247-25 · Cited by 2
Wunderlich, B., Feijoo, B., Limaye, R. J., Moulton, L. H., & Talaat, K. R. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2521192 · Cited by 2
Recent Advances in Audiological and Vestibular Research
Stavros Hatzopoulos, A., & Ciorba, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102239 · Cited by 2
Chavan, P., Dey, R., Castelino, R., Kamble, A., Poladia, P., Bagal, R., Jadhav, M., Shirsat, A., Chavan, A., Dhumal, S. B., et al. (2023) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2022-0150 · Cited by 3
It is time to include real-world effectiveness data on medicinal product labels
Dal‐Ré, R., Porcher, R., Rosendaal, F. R., & Schwarzer‐Daum, B. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00003-0 · Cited by 2
Singh, M. K., Jain, M., Shyam, H., Sahu, D. K., Mishra, A., Shankar, P., Kumar, S., & Singh, V. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07308-1 · Cited by 2
Gańczak, M., Korzeń, M., Sobieraj, E., Goławski, J., Pasek, O., & Biesiada, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19053111 · Cited by 2
Vu, D. M., Vu, D., Thuy, T. T., Olmsted, A. E., Dao, B. H., Thai, T. T., Nguyen, C. L., Le, N. T. T., Le, T. A., Bui, H. T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac493 · Cited by 2
“studies [13-15] and may be important for workforce management during the implementation of 2 future workplace ChAdOx1 nCoV-19 vaccination efforts.”
BackgroundShehab, M., Alrashed, F., Abdullah, I., Alfadhli, A., Ali, H., Abu‐Farha, M., Channanath, A. M., Abubaker, J. A., & Al‐Mulla, F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.881027 · Cited by 2
Lee, K., Park, I. H., Oh, S. C., Seo, J. H., Jeon, M. J., Yu, E. S., Kim, D. S., Choi, C. W., Lim, A.-R., Hyun, M. H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5400 · Cited by 2
González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., Pulido, H. G., Cervantes, O., Márquez‐Sandoval, F., Hernández‐Bello, J., Casillas, N., & Muñóz-Valle, J. F. (2023) · Vaccines · doi:10.3390/vaccines11040719 · Cited by 2
“95% CIs for the interest group published by the respective manufacturers for the BNT162b2 (- - -) [9] and AZD1222 (- - -) [10] vaccines.”
BackgroundInfluentialVagts, C. L., Sweis, J. J. G., Sweis, N. W. G., Ascoli, C., Rottoli, P., Martone, F. M., Wells, A. U., Judson, M. A., Sweiss, N., Lower, E. E., et al. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i2.14388 · Cited by 3
“Our findings, though retrospective and subject to recall bias, demonstrate that vaccination against COVID-19 was generally well tolerated in subjects with sarcoidosis with mild side effects in a minority of patients comparable to what is experienced by the general population (27-30).”
Ghorbani, S. S., Taherpour, N., Rahimi, E., Farhadi-Babadi, K., Feyzi, R., & Nazari, S. S. H. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.72 · Cited by 3
“There are only a few reports on the safety and effectiveness of AstraZeneca/Oxford and Janssen vaccines, and in these studies, pregnancy was the exclusion criterion (13, 14).”
BackgroundTraditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection
Shivangani, S., Lakshmi, N. J., Jamir, L., & Hariprasad, P. (2023) · Springer eBooks · doi:10.1007/978-981-99-3664-9_6 · Cited by 3
Makhema, J. M., Shava, E., Izu, A., Gaolathe, T., Kuate, L., Walker, A., Carty, L., Georgiou, P., Kgathi, C., Choga, W. T., et al. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.11.002 · Cited by 2
“[13] , whilst the study conducted in the United States, Chile and Peru by Falsey et al. [12] had the most reported AEs as headache (50.2%), fatigue (49.7%), muscle pains (41.9”
ResultInfluentialYang, K., Xu, K., Zhang, L., Han, Y., Zhou, D., Xia, Q., Dai, L., & Gao, G. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1054 · Cited by 4
Pool, S. N. T., Shroff, E. H., Chetty, A., Lewis, L., Yende‐Zuma, N., & Karim, S. S. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299747 · Cited by 3
“…populations eligible for the ChA-dOx1 nCoV-19 (SII Covishield) vaccine received their second dose at an extended dosing interval of 6–8 weeks; as evidenced by findings from phase 3 trials demonstrating higher antibody levels and greater vaccine efficacy with longer interdose intervals [10,11].”
MethodSendi, P., & Tande, A. J. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.04.012 · Cited by 2
“Vaccination is the evidence-based strategy against COVID-19, and its efficacy is proven in clinical trials [2,3].”
O’Neill, A., Kala, M. P., Tan, C. W., Saron, W. A. A., Mantri, C. K., Rathore, A. P. S., Wang, L., & John, A. L. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.09.507250 · Cited by 2
A simple non-invasive C reactive protein-based score can predict outcome in patients with COVID-19Preprint
Scotto, R., Lanzardo, A., Buonomo, A., Pinchera, B., Cattaneo, L., Sardanelli, A., Mercinelli, S., Viceconte, G., Zappulo, E., Villari, R., et al. (2022) · medRxiv · doi:10.1101/2022.09.29.22280522
“After 2 years of pandemic, the efforts in the research headed to the development of vaccines with excellent effectiveness and safety profile in the prevention of COVID-19 (2-4).”
BackgroundVaccination-Associated PathogenesisPreprint
Chang, C., Yu, C., Yang, C.-C., & Hsu, S. (2024) · Preprints.org · doi:10.20944/preprints202401.1689.v1 · Cited by 1
Replication‐Competent Viral Vectors for Vaccine Delivery
Chavda, V. P., Balar, P. C., Vaghela, D. A., Teli, D., Chaudhari, A. Z., & Alom, S. (2025) · doi:10.1002/9781394271566.ch4 · Cited by 2
Soegiarto, G., Fajar, J. K., Wulandari, L., Anshory, M., Ilmawan, M., Asmiragani, A., Illiyana, H., Adam, A., Lamadi, S., Sa'adah, U., et al. (2022) · F1000Research · doi:10.12688/f1000research.110281.1 · Cited by 1
Moore, M., Zhu, Y., Hirsch, I., White, T., Reiner, R. C., Barber, R. M., Pigott, D. M., Collins, J. K., Santoni, S., Sobieszczyk, M. E., et al. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100768 · Cited by 1
“Details of the prototypical trial design used by USG-funded COVID-19 VE trials are described elsewhere (Lora et al., 2023; Falsey et al., 2021; Baden et al., 2021; Sadoff et al., 2021; Dunkle et al., 2022; Mehrotra et al., 2021; Follmann et al., 2021).”
InfluentialSelf-citation
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.